|
US3400019A
(en)
*
|
1961-12-26 |
1968-09-03 |
Pullman Inc |
Electrode including nonmetallic substrate
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4518584A
(en)
|
1983-04-15 |
1985-05-21 |
Cetus Corporation |
Human recombinant interleukin-2 muteins
|
|
US5116943A
(en)
|
1985-01-18 |
1992-05-26 |
Cetus Corporation |
Oxidation-resistant muteins of Il-2 and other protein
|
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
|
FI903489A0
(fi)
|
1988-11-11 |
1990-07-10 |
Medical Res Council |
Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US5081235A
(en)
|
1989-07-26 |
1992-01-14 |
City Of Hope |
Chimeric anti-cea antibody
|
|
AU6290090A
(en)
|
1989-08-29 |
1991-04-08 |
University Of Southampton |
Bi-or trispecific (fab)3 or (fab)4 conjugates
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
DE69129154T2
(de)
|
1990-12-03 |
1998-08-20 |
Genentech, Inc., South San Francisco, Calif. |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
EP0940468A1
(en)
|
1991-06-14 |
1999-09-08 |
Genentech, Inc. |
Humanized antibody variable domain
|
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
|
DE69333807T2
(de)
|
1992-02-06 |
2006-02-02 |
Chiron Corp., Emeryville |
Marker für krebs und biosynthetisches bindeprotein dafür
|
|
US5229109A
(en)
|
1992-04-14 |
1993-07-20 |
Board Of Regents, The University Of Texas System |
Low toxicity interleukin-2 analogues for use in immunotherapy
|
|
EP1005870B1
(en)
|
1992-11-13 |
2009-01-21 |
Biogen Idec Inc. |
Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
|
US5798100A
(en)
|
1994-07-06 |
1998-08-25 |
Immunomedics, Inc. |
Multi-stage cascade boosting vaccine
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
EP0831880A4
(en)
|
1995-06-07 |
2004-12-01 |
Imclone Systems Inc |
ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
|
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
|
US7727761B2
(en)
|
1995-08-01 |
2010-06-01 |
Vegenics Limited |
Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
|
|
FR2757863B1
(fr)
|
1996-12-27 |
1999-03-26 |
Inovat Sarl |
Nouvelles substances a activite biologique, leur procede d'obtention et les compositions en renfermant
|
|
DK0979281T3
(da)
|
1997-05-02 |
2005-11-21 |
Genentech Inc |
Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
|
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
|
AU760562B2
(en)
|
1997-12-05 |
2003-05-15 |
Scripps Research Institute, The |
Humanization of murine antibody
|
|
DK1049787T3
(da)
|
1998-01-23 |
2005-04-04 |
Vlaams Interuniv Inst Biotech |
Antistofderivater med flere anvendelsesmuligheder
|
|
ES2434961T5
(es)
|
1998-04-20 |
2018-01-18 |
Roche Glycart Ag |
Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
EP1176195B1
(en)
|
1999-04-09 |
2013-05-22 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
|
HUP0202238A3
(en)
*
|
1999-07-12 |
2004-05-28 |
Idec Pharmaceuticals Inc San D |
Blocking immune response to a foreign antigen using an antagonist which binds to cd20
|
|
WO2001044463A1
(en)
|
1999-12-15 |
2001-06-21 |
Genentech, Inc. |
Shotgun scanning, a combinatorial method for mapping functional protein epitopes
|
|
EP1242438B1
(en)
|
1999-12-29 |
2006-11-08 |
Immunogen, Inc. |
Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
|
|
ES2637801T3
(es)
|
2000-04-11 |
2017-10-17 |
Genentech, Inc. |
Anticuerpos multivalentes y usos de los mismos
|
|
WO2002009573A2
(en)
|
2000-07-31 |
2002-02-07 |
The Brigham And Women's Hospital, Inc. |
Prognostic classification of endometrial cancer
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
JP3523245B1
(ja)
|
2000-11-30 |
2004-04-26 |
メダレックス，インコーポレーテッド |
ヒト抗体作製用トランスジェニック染色体導入齧歯動物
|
|
RU2321630C2
(ru)
|
2001-08-03 |
2008-04-10 |
Гликарт Биотекнолоджи АГ |
Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
|
|
EP1476180A4
(en)
|
2001-08-13 |
2005-04-20 |
Univ Southern California |
MUTANTS OF INTERLEUKIN-2 WITH REDUCED TOXICITY
|
|
US20030157108A1
(en)
|
2001-10-25 |
2003-08-21 |
Genentech, Inc. |
Glycoprotein compositions
|
|
BR0214650A
(pt)
|
2001-12-04 |
2005-05-03 |
Merck Patent Gmbh |
Imunocitoquinas com seletividade modulada
|
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
|
KR101001243B1
(ko)
|
2001-12-27 |
2010-12-17 |
글리코파이, 인크. |
포유동물-유형 탄수화물 구조의 설계 방법
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
JP4628679B2
(ja)
|
2002-04-09 |
2011-02-09 |
協和発酵キリン株式会社 |
Ｇｄｐ−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞
|
|
US20040132140A1
(en)
|
2002-04-09 |
2004-07-08 |
Kyowa Hakko Kogyo Co., Ltd. |
Production process for antibody composition
|
|
CN102911987B
(zh)
|
2002-04-09 |
2015-09-30 |
协和发酵麒麟株式会社 |
基因组被修饰的细胞
|
|
US20050031613A1
(en)
|
2002-04-09 |
2005-02-10 |
Kazuyasu Nakamura |
Therapeutic agent for patients having human FcgammaRIIIa
|
|
AU2003236018A1
(en)
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
|
|
JP4753578B2
(ja)
|
2002-06-03 |
2011-08-24 |
ジェネンテック， インコーポレイテッド |
合成抗体ファージライブラリー
|
|
SI1539966T1
(sl)
|
2002-09-12 |
2010-10-29 |
Greenovation Biotech Gmbh |
Postopek za produkcijo proteinov
|
|
PL216630B1
(pl)
|
2002-10-17 |
2014-04-30 |
Genmab As |
Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
|
|
ES2347241T3
(es)
|
2002-12-16 |
2010-10-27 |
Genentech, Inc. |
Variantes de inmunoglobulina y sus utilizaciones.
|
|
WO2004057002A2
(en)
|
2002-12-20 |
2004-07-08 |
Greenovation Biotech Gmbh |
Production of heterologous glycosylated proteins in bryophyte cells
|
|
EP2368578A1
(en)
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
US20050079574A1
(en)
|
2003-01-16 |
2005-04-14 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
|
PL222222B1
(pl)
|
2003-01-22 |
2016-07-29 |
Glycart Biotechnology Ag |
Sposób wytwarzania polipeptydu
|
|
JP2008501621A
(ja)
|
2003-05-31 |
2008-01-24 |
マイクロメット アクツィエン ゲゼルシャフト |
Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物
|
|
JP4948174B2
(ja)
|
2003-10-16 |
2012-06-06 |
マイクロメット アクツィエン ゲゼルシャフト |
多重特異的脱免疫ｃｄ３−結合物質
|
|
ES2672640T3
(es)
|
2003-11-05 |
2018-06-15 |
Roche Glycart Ag |
Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
|
|
CN107213469A
(zh)
|
2003-11-06 |
2017-09-29 |
西雅图基因公司 |
能够与配体偶联的单甲基缬氨酸化合物
|
|
PL1691833T3
(pl)
|
2003-11-28 |
2010-08-31 |
Amgen Res Munich Gmbh |
Kompozycje zawierające polipeptydy
|
|
US7235641B2
(en)
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
|
WO2005086875A2
(en)
|
2004-03-11 |
2005-09-22 |
City Of Hope |
A humanized anti-cea t84.66 antibody and uses thereof
|
|
RU2386638C2
(ru)
|
2004-03-31 |
2010-04-20 |
Дженентек, Инк. |
Гуманизированные анти-тфр-бета-антитела
|
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
|
CN1942483B
(zh)
|
2004-04-13 |
2012-09-26 |
弗·哈夫曼-拉罗切有限公司 |
抗p型选凝素抗体
|
|
US7850962B2
(en)
|
2004-04-20 |
2010-12-14 |
Genmab A/S |
Human monoclonal antibodies against CD20
|
|
CA2569509C
(en)
|
2004-06-03 |
2014-08-12 |
Novimmune S.A. |
Anti-cd3 antibodies and methods of use thereof
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
AR051836A1
(es)
|
2004-11-30 |
2007-02-14 |
Centocor Inc |
Antagonistas de receptor 3 simil toll metodos y usos
|
|
BRPI0607315B1
(pt)
|
2005-02-07 |
2022-05-17 |
Roche Glycart Ag |
Molécula de ligação ao antígeno anti-egfr humanizada e seus usos, composição farmacêutica, e método para detectar a presença de egfr em uma amostra
|
|
TWI671403B
(zh)
|
2005-03-31 |
2019-09-11 |
中外製藥股份有限公司 |
控制組裝之多肽的製造方法
|
|
US8475794B2
(en)
*
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
|
JP5129122B2
(ja)
|
2005-04-26 |
2013-01-23 |
トリオン ファーマ ゲーエムベーハー |
癌治療のための抗体およびグルココルチコイドの組み合わせ
|
|
WO2007039818A2
(en)
|
2005-05-09 |
2007-04-12 |
Glycart Biotechnology Ag |
Antigen binding molecules having modified fc regions and altered binding to fc receptors
|
|
ES2720160T3
(es)
|
2005-05-09 |
2019-07-18 |
Ono Pharmaceutical Co |
Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
|
|
EA019344B1
(ru)
|
2005-07-01 |
2014-03-31 |
МЕДАРЕКС, Эл.Эл.Си. |
Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
EP2500352A1
(en)
|
2005-08-19 |
2012-09-19 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
TWI478940B
(zh)
|
2005-08-26 |
2015-04-01 |
Roche Glycart Ag |
具有經改變細胞傳訊活性之改質抗原結合分子
|
|
EP1940881B1
(en)
|
2005-10-11 |
2016-11-30 |
Amgen Research (Munich) GmbH |
Compositions comprising cross-species-specific antibodies and uses thereof
|
|
EP1957531B1
(en)
|
2005-11-07 |
2016-04-13 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
|
|
EP1973951A2
(en)
|
2005-12-02 |
2008-10-01 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
|
JP5090366B2
(ja)
|
2005-12-16 |
2012-12-05 |
アイビーシー ファーマスーティカルズ，インク． |
多価イムノグロブリン系生物活性アセンブリー
|
|
WO2007071422A2
(en)
|
2005-12-21 |
2007-06-28 |
Micromet Ag |
Pharmaceutical antibody compositions with resistance to soluble cea
|
|
WO2007071426A1
(en)
|
2005-12-21 |
2007-06-28 |
Micromet Ag |
Pharmaceutical compositions with resistance to soluble cea
|
|
ES2395969T3
(es)
|
2006-03-24 |
2013-02-18 |
Merck Patent Gmbh |
Dominios de proteínas heterodiméricas genéticamente modificados
|
|
WO2007134050A2
(en)
|
2006-05-09 |
2007-11-22 |
Genentech, Inc. |
Binding polypeptides with optimized scaffolds
|
|
EP2418223A3
(en)
|
2006-06-12 |
2013-01-16 |
Emergent Product Development Seattle, LLC |
Single-chain multivalent binding proteins with effector function
|
|
EP2035456A1
(en)
|
2006-06-22 |
2009-03-18 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
|
EP2059533B1
(en)
|
2006-08-30 |
2012-11-14 |
Genentech, Inc. |
Multispecific antibodies
|
|
US8231706B2
(en)
|
2006-09-20 |
2012-07-31 |
Mt-Biomethan Gmbh |
Method and device for separating methane and carbon dioxide from biogas
|
|
WO2008119567A2
(en)
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific cd3-epsilon binding domain
|
|
RU2769948C2
(ru)
|
2007-04-03 |
2022-04-11 |
Эмджен Рисерч (Мьюник) Гмбх |
CD3-Эпсилон-связывающий домен с межвидовой специфичностью
|
|
AU2008234019B2
(en)
|
2007-04-03 |
2014-05-29 |
Amgen Research (Munich) Gmbh |
Cross-species-specific bispecific binders
|
|
CN100592373C
(zh)
|
2007-05-25 |
2010-02-24 |
群康科技(深圳)有限公司 |
液晶显示面板驱动装置及其驱动方法
|
|
WO2009061853A2
(en)
|
2007-11-05 |
2009-05-14 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (il-2) polypeptides
|
|
EP2225275A4
(en)
|
2007-11-28 |
2013-04-03 |
Medimmune Llc |
PROTEIN FORMULATION
|
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
SI2235064T1
(sl)
|
2008-01-07 |
2016-04-29 |
Amgen Inc. |
Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
|
|
EP2242773B1
(en)
|
2008-02-11 |
2017-06-14 |
Cure Tech Ltd. |
Monoclonal antibodies for tumor treatment
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
WO2009134738A1
(en)
*
|
2008-04-29 |
2009-11-05 |
Genentech, Inc. |
Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
|
|
EP2328920A2
(en)
|
2008-08-25 |
2011-06-08 |
Amplimmune, Inc. |
Targeted costimulatory polypeptides and methods of use to treat cancer
|
|
HUE065752T2
(hu)
|
2008-12-09 |
2024-06-28 |
Hoffmann La Roche |
Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
|
|
PE20120591A1
(es)
|
2009-04-02 |
2012-05-23 |
Roche Glycart Ag |
Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
|
|
CN102369214B
(zh)
|
2009-04-07 |
2019-04-12 |
罗氏格黎卡特股份公司 |
三价、双特异性抗体
|
|
CN102459346B
(zh)
|
2009-04-27 |
2016-10-26 |
昂考梅德药品有限公司 |
制造异源多聚体分子的方法
|
|
EP2435473B1
(en)
|
2009-05-27 |
2013-10-02 |
F.Hoffmann-La Roche Ag |
Tri- or tetraspecific antibodies
|
|
EP2261258A1
(de)
|
2009-06-08 |
2010-12-15 |
Schuler, Gerold |
MCSP-gerichtete scFv-Antikörperfragmente und deren Verwendung
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
US8703132B2
(en)
|
2009-06-18 |
2014-04-22 |
Hoffmann-La Roche, Inc. |
Bispecific, tetravalent antigen binding proteins
|
|
RU2570554C2
(ru)
|
2009-08-31 |
2015-12-10 |
Роше Гликарт Аг |
Гуманизированные моноклональные антитела к сеа с созревшей аффинностью
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
PT2504364T
(pt)
|
2009-11-24 |
2017-11-14 |
Medimmune Ltd |
Agentes de ligação direcionados contra b7-h1
|
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
SG181952A1
(en)
|
2009-12-29 |
2012-07-30 |
Emergent Product Dev Seattle |
Heterodimer binding proteins and uses thereof
|
|
WO2011100403A1
(en)
*
|
2010-02-10 |
2011-08-18 |
Immunogen, Inc |
Cd20 antibodies and uses thereof
|
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
|
CA2797981C
(en)
|
2010-05-14 |
2019-04-23 |
Rinat Neuroscience Corporation |
Heterodimeric proteins and methods for producing and purifying them
|
|
AU2011325833C1
(en)
|
2010-11-05 |
2017-07-13 |
Zymeworks Bc Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
PT3434767T
(pt)
|
2010-11-30 |
2026-01-23 |
Chugai Pharmaceutical Co Ltd |
Agente terapêutico indutor de citotoxicidade
|
|
US9266938B2
(en)
|
2011-02-10 |
2016-02-23 |
Roche Glycart Ag |
Mutant interleukin-2 polypeptides
|
|
BR112013021460B1
(pt)
|
2011-03-02 |
2022-12-20 |
Roche Glycart Ag |
Anticorpos, composição e uso do anticorpo
|
|
BR112013024574B1
(pt)
|
2011-03-29 |
2022-08-09 |
Roche Glycart Ag |
Anticorpo e uso do anticorpo
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
BR112013028537A2
(pt)
|
2011-05-06 |
2017-01-17 |
Us Gov Health & Human Serv |
imunotoxina recombinante que visa a mesotelina
|
|
WO2012158818A2
(en)
|
2011-05-16 |
2012-11-22 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
CN107827985A
(zh)
|
2011-05-21 |
2018-03-23 |
宏观基因有限公司 |
能够与人和非人cd3结合的cd3结合分子
|
|
WO2013012414A1
(en)
|
2011-07-18 |
2013-01-24 |
Medimmune, Llc |
Dosing regimens for treatment of cea-expressing cancers
|
|
CN107586340B
(zh)
|
2011-08-23 |
2022-01-21 |
罗切格利卡特公司 |
对t细胞活化性抗原和肿瘤抗原特异性的双特异性抗体及使用方法
|
|
AR087601A1
(es)
|
2011-08-23 |
2014-04-03 |
Roche Glycart Ag |
Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de utilizacion
|
|
HRP20181355T1
(hr)
|
2011-08-23 |
2018-10-19 |
Roche Glycart Ag |
Bispecifične molekule koje se vežu na antigen
|
|
PH12013502531A1
(en)
|
2011-08-23 |
2014-01-20 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
TW201326212A
(zh)
|
2011-08-23 |
2013-07-01 |
Roche Glycart Ag |
抗－ｍｃｓｐ抗體
|
|
WO2013026832A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Anti-mcsp antibodies
|
|
WO2013026837A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
EP2578230A1
(en)
|
2011-10-04 |
2013-04-10 |
Trion Pharma Gmbh |
Removal of Tumor Cells from Intraoperative Autologous Blood Salvage
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US20130302274A1
(en)
*
|
2011-11-25 |
2013-11-14 |
Roche Glycart Ag |
Combination therapy
|
|
HRP20201004T1
(hr)
|
2011-12-20 |
2020-10-16 |
Medimmune, Llc |
Modificirani polipeptidi za skelete bispecifičnog protutijela
|
|
DK2838917T3
(da)
|
2012-04-20 |
2019-08-26 |
Merus Nv |
Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler
|
|
US10202452B2
(en)
|
2012-04-20 |
2019-02-12 |
Aptevo Research And Development Llc |
CD3 binding polypeptides
|
|
WO2013186613A1
(en)
|
2012-06-14 |
2013-12-19 |
Nasvax Ltd. |
Humanized antibodies to cluster of differentiation 3 (cd3)
|
|
WO2013188693A1
(en)
|
2012-06-15 |
2013-12-19 |
Imaginab, Inc. |
Antigen binding constructs to cd3
|
|
US20150203591A1
(en)
|
2012-08-02 |
2015-07-23 |
Regeneron Pharmaceuticals, Inc. |
Mutivalent antigen-binding proteins
|
|
CN104662045B
(zh)
|
2012-08-07 |
2019-04-05 |
罗切格利卡特公司 |
包含两种工程化改造成具有降低的和升高的效应器功能的抗体的组合物改进的免疫疗法
|
|
EP2885002A4
(en)
|
2012-08-14 |
2016-04-20 |
Ibc Pharmaceuticals Inc |
BISPECIFIC ANTIBODIES REDIRECTED AGAINST T CELLS FOR THE TREATMENT OF DISEASES
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
BR112015007120A2
(pt)
*
|
2012-10-08 |
2017-12-12 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
CN105051069B
(zh)
|
2013-01-14 |
2019-12-10 |
Xencor股份有限公司 |
新型异二聚体蛋白
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
ES2667420T3
(es)
|
2013-02-05 |
2018-05-10 |
Engmab Sàrl |
Anticuerpos biespecíficos contra cd3epsilon y bcma
|
|
JO3529B1
(ar)
|
2013-02-08 |
2020-07-05 |
Amgen Res Munich Gmbh |
مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
|
|
WO2014131711A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
CN110845618A
(zh)
|
2013-02-26 |
2020-02-28 |
罗切格利卡特公司 |
双特异性t细胞活化抗原结合分子
|
|
UA119320C2
(uk)
|
2013-02-26 |
2019-06-10 |
Рош Глікарт Аг |
Активуюча т-клітини біспецифічна антигензв'язувальна молекула
|
|
US10351626B2
(en)
|
2013-03-14 |
2019-07-16 |
The Scripps Research Institute |
Targeting agent antibody conjugates and uses thereof
|
|
US20140302037A1
(en)
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
TW201501724A
(zh)
|
2013-03-15 |
2015-01-16 |
Glaxosmithkline Ip No 2 Ltd |
低濃度抗體調配物
|
|
PL3587448T3
(pl)
|
2013-03-15 |
2021-11-29 |
Xencor, Inc. |
Białka heterodimeryczne
|
|
EP2789630A1
(en)
|
2013-04-09 |
2014-10-15 |
EngMab AG |
Bispecific antibodies against CD3e and ROR1
|
|
AR096183A1
(es)
*
|
2013-05-02 |
2015-12-16 |
Hoffmann La Roche |
Terapia de combinación de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd79b-fármaco
|
|
ES2693370T3
(es)
*
|
2013-05-02 |
2018-12-11 |
F. Hoffmann-La Roche Ag |
Politerapia de un anticuerpo CD20 afucosilado con un conjugado de anticuerpo CD22-fármaco
|
|
HK1217023A1
(zh)
|
2013-05-28 |
2016-12-16 |
Numab Innovation Ag |
新型抗体
|
|
HUE048722T2
(hu)
|
2013-07-05 |
2020-08-28 |
Genmab As |
Humanizált vagy kiméra CD3 ellenanyagok
|
|
MX2016007885A
(es)
*
|
2013-12-17 |
2017-01-11 |
Genentech Inc |
Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20.
|
|
NZ760065A
(en)
|
2013-12-17 |
2022-12-23 |
Genentech Inc |
Methods of treating cancers using pd-1 axis binding antagonists and taxanes
|
|
KR102225489B1
(ko)
|
2013-12-17 |
2021-03-10 |
제넨테크, 인크. |
항-cd3 항체 및 이의 사용 방법
|
|
CA2932547C
(en)
|
2014-01-06 |
2023-05-23 |
F. Hoffmann-La Roche Ag |
Monovalent blood brain barrier shuttle modules
|
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
|
US20170073415A1
(en)
|
2014-05-12 |
2017-03-16 |
Numab Ag |
Novel multispecific molecules and novel treatment methods based on such multispecific molecules
|
|
JP6738285B2
(ja)
|
2014-05-28 |
2020-08-12 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
ヒト及びカニクイザルｃｄ３イプシロンに結合する抗体
|
|
AU2015292406B2
(en)
|
2014-07-25 |
2021-03-11 |
Cytomx Therapeutics, Inc |
Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
|
|
SMT202400235T1
(it)
|
2014-08-04 |
2024-07-09 |
Hoffmann La Roche |
Molecole bispecifiche leganti l’antigene di attivazione delle cellule t
|
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
EP2982693A1
(en)
|
2014-08-07 |
2016-02-10 |
Affimed Therapeutics AG |
CD3 binding domain
|
|
WO2016019969A1
(en)
|
2014-08-08 |
2016-02-11 |
Ludwig-Maximilians-Universität München |
Subcutaneously administered bispecific antibodies for use in the treatment of cancer
|
|
WO2016030350A1
(en)
|
2014-08-29 |
2016-03-03 |
F. Hoffmann-La Roche Ag |
Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
|
|
WO2016036678A1
(en)
|
2014-09-02 |
2016-03-10 |
Medimmune, Llc |
Formulations of bispecific antibodies
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
US20170306044A1
(en)
|
2014-10-09 |
2017-10-26 |
Engmab Ag |
Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
|
|
AU2015329965A1
(en)
|
2014-10-09 |
2017-04-27 |
Engmab Sàrl |
Bispecific antibodies against CD3epsilon and ROR1
|
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
RS61010B1
(sr)
|
2014-11-20 |
2020-11-30 |
Hoffmann La Roche |
Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
|
|
BR112017010513A2
(pt)
|
2014-11-20 |
2018-04-03 |
F. Hoffmann-La Roche Ag |
?cadeias leves comuns e métodos de uso?
|
|
EP3029068A1
(en)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
|
HK1250997A1
(zh)
|
2015-05-01 |
2019-01-18 |
基因泰克公司 |
掩蔽抗cd3抗体和使用方法
|
|
ES2957567T3
(es)
|
2015-06-16 |
2024-01-22 |
Hoffmann La Roche |
Anticuerpos humanizados y de afinidad madurada contra FcRH5 y procedimientos de uso
|
|
EP3670535A1
(en)
|
2015-08-03 |
2020-06-24 |
EngMab Sàrl |
Monoclonal antibodies against bcma
|
|
EP3913000A1
(en)
|
2015-10-02 |
2021-11-24 |
F. Hoffmann-La Roche AG |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
|
US20170096485A1
(en)
|
2015-10-02 |
2017-04-06 |
Hoffmann-La Roche Inc. |
Bispecific t cell activating antigen binding molecules
|
|
KR20180073561A
(ko)
|
2015-10-02 |
2018-07-02 |
에프. 호프만-라 로슈 아게 |
이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자
|
|
WO2017055318A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Cd33xcd3 bispecific t cell activating antigen binding molecules
|
|
EP3356409A2
(en)
|
2015-10-02 |
2018-08-08 |
H. Hoffnabb-La Roche Ag |
Bispecific t cell activating antigen binding molecules
|
|
ES2901794T3
(es)
|
2015-12-09 |
2022-03-23 |
Hoffmann La Roche |
Anticuerpo anti-CD20 de tipo II para reducir la formación de anticuerpos antifármaco
|
|
US11466094B2
(en)
|
2016-11-15 |
2022-10-11 |
Genentech, Inc. |
Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
|